Moderna Inc (MRNA)

[jondoeuk]

AACR in late April

CT251 / 20 - Phase 3 INTerpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIB (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy https://www.abstractsonline.com/pp8/#!/20273/presentation/10620

855 / 11 - Dynamics of T cell and T cell receptor following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial https://www.abstractsonline.com/pp8/#!/20273/presentation/1971

3127 / 12 - An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies https://www.abstractsonline.com/pp8/#!/20273/presentation/3030